Navigation Links
Cohera Medical and CEO Receive Pittsburgh Tech 50 Awards
Date:9/21/2011

PITTSBURGH, Sept. 21, 2011 /PRNewswire/ -- Cohera Medical, a rapidly growing medical device company, announced today that the Company has received two Pittsburgh Technology Council Tech 50 Awards. Cohera Medical was recognized as the 2011 Life Sciences Company of the Year and its President and Chief Executive Officer, Patrick Daly, was named Pittsburgh CEO of the Year.

"We are honored to be recognized by the Pittsburgh Technology Council as a company that is developing unique and innovative technology that will help surgeons improve the overall care of their patients," said Patrick Daly. "These awards are a reflection of the quality, commitment and passion of our entire team.  We remain fully committed to supporting the technology business in southwest Pennsylvania and making a positive impact on the lives of patients and surgeons worldwide."

The Pittsburgh Technology Council's Tech 50 Awards recognize southwestern Pennsylvania's technology and thought-leading companies, which are innovation pioneers in technology-based industries that have become the backbone of Pittsburgh's new economy. The council has over 270,000 members from more than 1,400 companies across the southwestern Pennsylvania region.

The Life Sciences Company of the Year award is given to a company in the life sciences sector that improves our health and environment.  The Pittsburgh CEO of the Year award is given to a CEO of a Tech 50 category company who makes a substantial contribution to his or her company performance and demonstrates outstanding leadership and high levels of peer esteem.  

"Each year, the Pittsburgh Technology Council's Tech 50 Awards honor those technology companies that demonstrate the strongest growth and advancement in products or sales success, financial strength, corporate citizenship, job growth and retention and innovative product or technology," said Audrey Russo, President and CEO  of the Pittsburgh Tech Council.  "We congratulate Cohera Medical, Patrick Daly and its employees on this accomplishment."

Cohera Medical recently received CE mark approval of its lead product in development, TissuGlu® Surgical Adhesive. CE Mark approval allows TissuGlu to be sold in the European Union and the company plans to begin commercialization in Germany in the third quarter of 2011. Cohera Medical is also actively pursing U.S. FDA approval.

About Cohera Medical

Cohera Medical, Inc.® is a rapidly growing medical device company that is actively developing a line of surgical adhesives. Cohera Medical's products are based on a unique chemical design that is resorbable, non-toxic, easy-to-use, and forms a strong bond between tissue layers. The Company's lead product, TissuGlu® Surgical Adhesive, is designed to reduce fluid accumulation and the need for surgical drains in patients undergoing abdominoplasty (tummy tuck) and other plastic procedures that require the creation of large planar flaps of tissue. Cohera Medical is also developing surgical adhesives for use as bowel sealants, for hernia mesh fixation and for small bone fixation. Outside of the EU, TissuGlu Surgical Adhesive and the other Cohera products are currently indicated for investigational use only and have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or in any other market

For more information, visit www.coheramed.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.


'/>"/>
SOURCE Cohera Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Treated in Clinical Study of Cohera Medicals TissuGlu(R) Surgical Adhesive
2. Frost & Sullivan Recognizes Cohera Medical, Inc.® for Developing TissuGlu®, Its Pioneering Surgical Adhesive That Is Strong, Easy-To-Use, Biocompatible and Resorbable
3. Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Globus Medical Raises $110 Million in Series E Financing Round
8. Quark Pharmaceuticals Appoints New Chief Medical Officer
9. Boston University Biomedical Engineers Find Chink in Bacterias Armor
10. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
11. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
(Date:10/4/2017)... the Centers for Disease Control and Prevention (CDC), influenza vaccination should ... helping communities across Massachusetts , Connecticut ... shots through the end of the month. *Some exclusions apply ... ... is by the end of October, according to the Centers for Disease ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
Breaking Medicine News(10 mins):